

## **Supplementary Information**

### **A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis and rate of progression**

Penny J. Norsworthy; Andrew G.B. Thompson; Tze H. Mok; Ross W. Paterson; Jonathan M. Schott;  
John Collinge; Simon Mead; and Emmanuelle A. Viré

Corresponding author: Prof. Simon Mead, MRC Prion Unit at UCL, UCL Institute of Prion Diseases,  
London, UK. Email: s.mead@prion.ucl.ac.uk

#### **Contents:**

Supplementary Table 1 (In separate Excel file) Partek Gene Specific Analysis of small RNA-seq data

Supplementary Table 2 Effect of adjustment for RNA Integrity Number (RIN) on small RNA-seq differential expression results

Supplementary Table 3 Gene set enrichment analysis of differentially expressed (DE) miRNA target genes: output from Jensen TISSUES

Supplementary Fig.1 *PRNP* codon 129 genotype and expression of differentially expressed (DE) miRNAs in discovery cohort sCJD patients

Supplementary Fig.2 Validation and replication of DE miRNAs measured by qRT-PCR

Supplementary Fig.3 Raw Ct values in control and sCJD groups for mRNA target endogenous control RNAs

Supplementary Fig.4 Expression of replicated DE miRNAs in AD measured by qRT-PCR

Supplementary Fig.5 Relationship between disease progression and change in DE miRNA levels in longitudinal samples from sCJD patients (control RNA SNORD42B)

Supplementary Fig.6 Relationship between disease progression and change in DE miRNA levels in longitudinal samples from sCJD patients (control RNA SNORD95)

Supplementary Fig.7 Expression of *MCM7* in replication cohort controls and sCJD patients

**Supplementary Table 2** Effect of adjustment for RNA Integrity Number (RIN) on small RNA-seq differential expression results


	Small RNA-seq Gene Specific Analysis (GSA)		RIN included as covariate in GSA		RIN <4 excluded (sCJD n=50, Control n=48) <sup>a</sup>	
microRNA	Adjusted p-value	Fold change (sCJD vs. Control)	Adjusted p-value	Fold change (sCJD vs. Control)	Adjusted p-value	Fold change (sCJD vs. Control)
hsa-miR-93-5p	0.00037	-2.48	0.00073	-2.55	0.00044	-2.52
hsa-miR-106b-3p	0.00637	-1.75	0.02	-1.64	0.00359	-1.73
hsa-let-7i-5p	0.00637	-2.63	0.02	-2.49	0.00626	-2.77
hsa-miR-16-5p	0.00637	-2.47	0.02	-2.36	0.00626	-2.55
hsa-let-7d-3p	0.019	2.00	0.02	2.06	0.03	2.06

<sup>a</sup>After nine RNA samples with RIN<4 were excluded, 50 samples from sCJD patients and 48 control samples remained in the analysis.

**Supplementary Table 3** Gene set enrichment analysis of differentially expressed (DE) miRNA target genes<sup>a</sup>: output from Jensen TISSUES<sup>b</sup>


Term	P-value	Adjusted P-value	Odds Ratio	Combined Score	Genes
Pancreatic cancer cell	1.79E-04	0.030	95.238	821.47	CDKN1A;VEGFA
Bronchial epithelial cell	2.00E-04	0.031	4.135	35.22	RNF44;CCND3;ZFP36;CDKN1A;NAP1L1;VEGFA
Pancreatic islet	2.36E-04	0.031	4.023	33.60	RNF44;CCND3;ZFP36;CDKN1A;NAP1L1;VEGFA
Embryonic brain	2.25E-04	0.032	4.052	34.03	RNF44;CCND3;ZFP36;CDKN1A;NAP1L1;VEGFA
Superior cervical ganglion	1.77E-04	0.033	4.219	36.46	RNF44;CCND3;ZFP36;CDKN1A;NAP1L1;VEGFA
Adrenal cortex	1.43E-04	0.033	4.373	38.72	RNF44;CCND3;ZFP36;CDKN1A;NAP1L1;VEGFA
Colorectal cancer cell	1.69E-04	0.035	98.039	851.33	CDKN1A;VEGFA
Parenchyma	2.95E-04	0.036	3.874	31.48	RNF44;CCND3;ZFP36;CDKN1A;NAP1L1;VEGFA
Ovary cancer cell line	1.41E-04	0.037	107.527	953.65	CDKN1A;VEGFA
Neointima	1.23E-04	0.038	114.943	1034.82	CDKN1A;VEGFA
Amygdala	3.37E-04	0.039	3.789	30.29	RNF44;CCND3;ZFP36;CDKN1A;NAP1L1;VEGFA
Erythroid cell	1.21E-04	0.044	4.496	40.57	RNF44;CCND3;ZFP36;CDKN1A;NAP1L1;VEGFA
Ophthalmic nerve	2.64E-05	0.049	5.792	61.06	RNF44;CCND3;ZFP36;CDKN1A;NAP1L1;VEGFA
Eye	4.49E-04	0.049	3.613	27.85	RNF44;CCND3;ZFP36;CDKN1A;NAP1L1;VEGFA
Prefrontal cortex	4.98E-04	0.051	3.551	27.01	RNF44;CCND3;ZFP36;CDKN1A;NAP1L1;VEGFA

<sup>a</sup>Input gene list: RNF44;CCND3;ZFP36;CDKN1A;NAP1L1;VEGFA; <sup>b</sup>Top 15 tissues ranked by adjusted p value are shown.




**Supplementary Fig.1** *PRNP* codon 129 genotype and expression of differentially expressed (DE) miRNAs in discovery cohort sCJD patients


Normalised transcript counts (in Fragments Per Kilobase of transcript per Million mapped reads, FPKM) were plotted with respect to *PRNP* codon 129 genotype (MM, MV, VV). Median and interquartile range are shown




**Supplementary Fig.2 Validation and replication of DE miRNAs measured by qRT-PCR** Expression of DE miRNAs relative to the control small RNA SNORD42B (a), hsa-let-7i-5p Fold change (FC) -1.75; hsa-miR-16-5p FC -1.82; hsa-miR-93-5p FC -1.70; hsa-let-7d-3p FC 1.14; hsa-miR-484 FC 1.13; SNORD95 (b) hsa-let-7i-5p FC -1.64; hsa-miR-16-5p FC -1.65; hsa-miR-93-5p FC -1.54; hsa-let-7d-3p FC 1.29; hsa-miR-484 FC 1.21; and SNORD72 (c) hsa-let-7i-5p FC -1.99; hsa-miR-16-5p FC -2.07; hsa-miR-93-5p FC -1.93; hsa-let-7d-3p FC 1.05; hsa-miR-484 FC 1.00; with median and interquartile range, are shown for both control and sCJD groups. Raw Ct values (d) were plotted for all four control small RNAs, and are shown with median and interquartile range in both control and sCJD groups. \*p<0.05




**Supplementary Fig.3 Raw Ct values in control and sCJD groups for mRNA target endogenous control RNAs** Ct values were plotted for all three endogenous control RNAs (shown on x axis), and are shown with mean and standard deviation in both control and sCJD groups




**Supplementary Fig.4 Expression of replicated DE miRNAs in AD measured by qRT-PCR** Expression of DE miRNAs relative to the control small RNA SNORD42B (a), hsa-let-7i-5p FC 2.36; hsa-miR-16-5p FC 2.69; hsa-miR-93-5p FC 1.94; SNORD95 (b) hsa-let-7i-5p FC 2.57; hsa-miR-16-5p FC 2.96; hsa-miR-93-5p FC 2.14; and SNORD72 (c) hsa-let-7i-5p FC 2.91; hsa-miR-16-5p FC 3.15; hsa-miR-93-5p FC 2.12; with median and interquartile range, are shown for both control and AD groups. Raw Ct values (d) were plotted for all four control small RNAs, and are shown with median and interquartile range in both control and AD groups. \*\* $p<0.01$  \*\*\* $p<0.001$



**Supplementary Fig.5 Relationship between disease progression and change in DE miRNA levels in longitudinal samples from sCJD patients (control RNA SNORD42B)** miRNA expression was measured relative to the control small RNA SNORD42B for (a) hsa-let-7i-5p, (b) hsa-miR-16-5p, (c) hsa-miR-93-5p and (d) hsa-miR-484. hsa-miR-484 is a non-DE microRNA shown here for comparison. %Loss of function per day was calculated from decline in MRC Scale Score.  $R^2$  and p values are shown. Dotted lines represent 95% confidence intervals. Data points are colour coded by *PRNP* codon 129 genotype (MM blue triangle, MV magenta diamonds, VV inverted green triangles)



**Supplementary Fig.6 Relationship between disease progression and change in DE miRNA levels in longitudinal samples from sCJD patients (control RNA SNORD95)** miRNA expression was measured relative to the control small RNA SNORD95 for (a) hsa-let-7i-5p, (b) hsa-miR-16-5p, (c) hsa-miR-93-5p and (d) hsa-miR-484. hsa-miR-484 is a non-DE microRNA shown here for comparison. %Loss of function per day was calculated from decline in MRC Scale Score.  $R^2$  and  $p$  values are shown. Dotted lines represent 95% confidence intervals. Data points are colour coded by *PRNP* codon 129 genotype (MM blue triangle, MV magenta diamonds, VV inverted green triangles)



**Supplementary Fig.7 Expression of *MCM7* in replication cohort controls and sCJD patients** Expression of *MCM7* plotted relative to combined expression of control mRNAs (*ALAS1*, *B2M* and *ACTB*). Median and range are shown. Median FC is -1.30 in sCJD patients compared to controls; \*p <0.05